Loading...
Loading...
Ranked by Compass Score · 20 companies · Updated June 10, 2026
The most hyped biotech names heading into 2026 carry the same problem they always do: the crowd got there first. By the time a GLP-1 story is on the front page of every financial publication, or a gene-editing platform has been written up by every sell-side desk, the easy money has already moved on. The premium you pay for certainty in biotech is rarely worth it, because certainty in this sector is mostly a story people tell themselves.
What the Compass Score does is strip that story away. Eight factors, weighted and scored, looking across clinical pipeline depth, balance sheet durability, revenue trajectory, competitive positioning, and a few less obvious variables that consensus models tend to ignore. The output is a ranked list of companies where the risk-to-reward math actually holds up, not the ones with the best press releases or the most familiar names. Start there.
Get our top Biotech & Genomics ideas, free
The Alexandria e-letter delivers our highest-conviction picks, earnings intelligence, and contrarian calls twice a week. Join free.
Free forever. Unsubscribe anytime. We never share your email.
Higher Compass Scores reflect where fundamentals, momentum, and forward catalysts align. Tap any company for the full breakdown.
Standout: Market Position (86/100) · Direction: Accumulate · $30.2B
Standout: Market Position (97/100) · Direction: Accumulate · $1.02T
Standout: Revenue Growth (98/100) · Direction: Accumulate · $3.7B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $6.0B
Standout: Theme Purity (99/100) · Direction: Accumulate · $39.7B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $3.1B
Standout: Momentum (89/100) · Direction: Accumulate · $3.5B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.3B
Standout: Momentum (86/100) · Direction: Accumulate · $9.1B
Standout: Theme Purity (99/100) · Direction: Hold · $4.0B
Standout: Revenue Growth (86/100) · Direction: Accumulate · $8.5B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $7.6B
Standout: Theme Purity (99/100) · Direction: Accumulate · $5.1B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $5.0B
Standout: Profitability (90/100) · Direction: Accumulate · $2.0B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $2.7B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $4.7B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $1.3B
Standout: Revenue Growth (98/100) · Direction: Accumulate · $947M
Standout: Revenue Growth (98/100) · Direction: Accumulate · $1.4B
By Alexandria's Compass Score, DexCom Inc. (NASDAQ:DXCM) currently ranks highest among Biotech & Genomics names with a score of 91/100 (True North). Compass Scores are recomputed weekly across eight factors, so rankings shift as the fundamentals do.
Every company is scored 1-100 on eight weighted factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The composite is percentile-normalized into a Compass Score and a tier from True North to Avoid. It is a contrarian lens that rewards what the crowd overlooks rather than what is already priced in.
A high Compass Score reflects where fundamentals, momentum, and forward catalysts align. It is research, not investment advice. Use the ranking as a starting point, then read each company's full Compass Direction analysis before making any decision.
Get the contrarian edge, free
Join the Alexandria e-letter for top-rated stocks, earnings intelligence, and the take the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Compass Scores are proprietary editorial research generated by Alexandria's analysis engine from publicly available data. They are one data point among many and do not constitute investment advice or a recommendation regarding any security. Rankings update weekly and may change.